Skip to content Skip to footer
Subscribe Now
NEWS

Basilea Pharmaceutica Enters Into a Licensing Deal with Venatorx Pharmaceuticals

Shots: Basilea Pharmaceutica entered into an exclusive license deal with Venatorx Pharmaceuticals to acquire global rights to ceftibuten-ledaborbactam etzadroxil, a P-III oral beta-lactam/beta-lactamase inhibitor (BL/BLI) combination for complicated urinary tract infections (cUTI), incl. pyelonephritis Under the agreement, Venatorx will receive an upfront payment along with potential milestone payments in 2025 and will also be eligible…
August 14, 2025

Read more

NEWS

Bayer Enters a ~$1.3B Deal with Kumquat Biosciences to Develop and Commercialize a KRAS G12D Inhibitor

Shots: Bayer has entered into an exclusive global license agreement & collaboration with Kumquat Biosciences to develop and commercialize its KRAS G12D inhibitor Kumquat will initiate & complete the P-Ia study following FDA’s IND clearance in Jul 2025, while Bayer handles further development & commercialization, with Kumquat holding an exclusive option to negotiate US profit-loss…
August 13, 2025

Read more

NEWS

Lupin Collaborates with Sandoz to Commercialize Ranibizumab Biosimilar

Shots: Lupin has entered into a licensing agreement with Sandoz to market & commercialize Lupin’s ranibizumab biosimilar in multiple regions As per the deal, Sandoz will commercialize the product in the EU (excl. Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, & Malaysia, while holding exclusive rights in most markets & semi-exclusive rights in France, Australia,…
August 12, 2025

Read more

Kashiv Biosciences & MS Pharma
NEWS

Kashiv BioSciences and MS Pharma Sign MENA License & Supply Deal for ADL-018 (Biosimilar, Xolair)

Shots: Kashiv BioSciences and MS Pharma have signed a license & supply agreement for ADL-018, a Xolair (omalizumab) biosimilar, across the Middle East and North Africa (MENA) region, with anticipated regulatory submissions in Q4’25 Under the agreement, Kashiv BioSciences will develop ADL-018, while MS Pharma will handle licensing, distribution, and commercialization in MENA, with local…
August 6, 2025

Read more

NEWS

Madrigal Pharmaceuticals Signs a ~$2.1B Licensing Deal with CSPC Pharmaceutical for SYH2086

Shots: Madrigal has secured an exclusive global license from CSPC to develop, manufacture, & commercialize SYH2086 for advancing innovative combination therapies targeting MASH As per the deal, CSPC will receive $120M upfront & ~$2B in development, regulatory & commercial milestones, with net sales-based royalties; CSPC may also develop other oral GLP-1s in China under certain…
July 30, 2025

Read more

NEWS

HanchorBio Out-Licenses HCB101 to Shanghai Henlius Biotech For ~$202M

Shots: HanchorBio entered into an out-licensing agreement with Shanghai Henlius Biotech and granted exclusive rights to develop and commercialize HCB101 in Greater China, Southeast Asia, and MENA Under the terms and agreement, HanchorBio will receive $10M upfront and up to $192M in development and regulatory milestones, plus tiered royalties Henlius will also oversee development, production,…
July 1, 2025

Read more

Velavigo
NEWS

Ollin Biosciences Signs a ~$440M Licensing Agreement with VelaVigo Bio for VBS-102

Shots: VelaVigo Bio has granted Ollin Biosciences an exclusive license to develop, manufacture & commercialize VBS-102 worldwide, except Greater China, where VelaVigo will maintain its rights As per the deal, VelaVigo will receive an upfront payment along with development, regulatory, & commercial milestones in cash & equity, making an aggregate of ~$440M, plus tiered royalties…
April 21, 2025

Read more